In 2008, the six tumor types covered in this report are forecast to account for over 666,000 new cases of cancer, obviously representing an enormous market potential. However, it is the higher-incidence tumor types that continue to attract drug developers, with lower-incidence cancers potentially suffering due to unfulfilled unmet needs via a lack of R&D activity.

Scope

Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types
Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types
Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs

Report Highlights

A low level of interest from drug developers means unmet needs in the SCLC, mesothelioma, primary brain and thyroid cancer markets are likely to remain unfulfilled. Drug developers should realize that despite being low-incidence tumor types, high unmet needs could result in significant financial rewards and a foothold in the market to build upon.

Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono) shows the most promise in the current NSCLC pipeline. Recent clinical trial results mean Erbitux may become a viable option in the first-line treatment of NSCLC, particularly for those patients ineligible for Avastin (bevacizumab; Genentech/Roche) therapy.

Vectibix (panitumumab; Amgen) and zalutumumab (HuMax-EGFR; Genmab/Medarex) show great promise to compete with Erbitux in the head and neck cancer market, particularly due to potential toxicity advantages that fully human monoclonal antibodies may have.

Reasons to Purchase

Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment
Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction
Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products

ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the cancer market
- Contributing experts
- Related reports
- Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
  - Late-phase pipeline
  - Pipeline by indication
    - The higher-incidence tumor types remain the most popularindications for drug development
CHAPTER 3 R&D APPROACH
- Classification of pipeline products
  - Cytotoxics
  - Antihormonal therapies
  - Molecular targeted therapies
    - Single-target signal transduction inhibitors
    - Angiogenesis inhibitors
    - Apoptosis inducers
    - Cell cycle inhibitors
    - Multi-targeted inhibitors
    - Epigenetic modulators
  - Immunotherapeutic agents
CHAPTER 4 NON-SMALL CELL LUNG CANCER
- Overview of NSCLC
  - Definition
    - NSCLC accounts for about 80% of all lung cancers
  - Epidemiology
    - There will be more than 380,000 new cases of NSCLC in theseven major markets in 2017
    - Mortality from NSCLC is high
  - Treatment of NSCLC
- Unmet needs in NSCLC
  - Summary of unmet needs
    - Effective treatments are required for both advanced andearly-stage disease
    - NSCLC needs to be recognized as a heterogeneous disease
    - Less toxic treatments for poor performance status patientsare required
    - The treatment of NSCLC is in need of overall refinement
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Erbitux (cetuximab; ImClone/Merck Serono/Bristol-MyersSquibb)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Nexavar (sorafenib; Bayer Schering)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Sutent (sunitinib; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Tovok (BIBW 2992; Boehringer Ingelheim)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Vargatef (BIBF 1120; Boehringer-Ingelheim)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Zactima (vandetanib; AstraZeneca)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Zolinza (vorinostat; Merck & Co)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Aflibercept (VEGF-Trap; Sanofi-Aventis/Regeneron)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - ASA-404 (Antisoma/Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - CBT-1 (CBA Pharma)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - CP-751871 (Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Motesanib (AMG706; Amgen/Takeda Pharmaceutical)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Abraxane (albumin-bound paclitaxel; Abraxis)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Glutoxim (NOV-002; Novelos)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Javlor (vinflunine; Pierre Fabre)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Lipoplatin (liposomal cisplatin; Regulon)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Taxoprexin (DHA paclitaxel; Luitpold)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Opaxio (paclitaxel polyglumex; Cell Therapeutics/Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Lucanix (NovaRx)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Stimuvax (BLP-25; Merck Serono)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - MAGE-A3 ASCI (GSK1572932A; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Approval of pipeline drugs will offer alternativetreatment options, however, are unlikely to significantly fulfil unmetneeds
CHAPTER 5 SMALL CELL LUNG CANCER
- Overview of SCLC
  - Definition
  - Epidemiology
    - The incidence of SCLC is decreasing with declining smokingprevalence
    - Poor survival rates result in a high mortality from SCLC
  - Treatment of SCLC
- Unmet needs in SCLC
  - Summary of unmet needs
    - There is a need for more effective systemic therapies toimprove patient survival
    - R&D activity in the field must be intensified
    - A better understanding of the molecular basis of thedisease may help in the development of novel targeted agents
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Picoplatin (AMD-473; Poniard Pharmaceuticals)
    - Drug overview
    - Key historical events
    - Clinical development in SCLC
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Picoplatin is unlikely to offer any significantimprovements in terms of patient survival
CHAPTER 6 MESOTHELIOMA
- Overview of mesothelioma
  - Definition
    - Mesothelioma is almost always caused by sustained exposureto asbestos
  - Epidemiology
    - Forecast incidence is difficult to predict formesothelioma, although the cancer is relatively rare
    - Survival rates for mesothelioma have improved minimallyover the years
  - Treatment of mesothelioma
- Unmet need in mesothelioma
  - Summary of unmet needs
    - Increasing incidence and need for earlier diagnosis
    - Low rate of curative surgery
    - Lack of approved therapies and low R&D interest
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Onconase (Alfacell Corp; ranpirnase)
    - Drug overview
    - Key historical events
    - Clinical development in mesothelioma
    - Datamonitor comments
  - Zolinza (vorinostat; Merck & Co)
    - Drug overview
    - Key historical events
    - Clinical development in mesothelioma
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Onconase and Zolinza meet some unmet needs in terms ofproviding much needed alternative treatment options
CHAPTER 7 PRIMARY BRAIN CANCER
- Overview of primary brain cancer
  - Definition
    - Glioma is the most common type of primary brain cancer
  - Epidemiology
    - Incidence of brain cancer is rising in line with theageing population
    - Mortality from brain cancer is very high in comparison toits incidence
  - Treatment of primary brain cancer
- Unmet need in primary brain cancer
  - Summary of unmet needs
    - More effective chemotherapy options needed
    - Blood-brain barrier may prove an obstacle to overcome
    - Need for neuroprotective therapy
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Theraloc (nimotuzumab; YM Biosciences/BioconBiopharmaceuticals)
    - Drug overview
    - Key historical events
    - Clinical development in brain cancer
    - Datamonitor comments
  - Cerepro (sitimagene ceradenovec; Ark Therapeutics)
    - Drug overview
    - Key historical events
    - Clinical development in brain cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Temodar will retain its leading status for some time tocome in the primary brain cancer market
CHAPTER 8 HEAD AND NECK CANCER
- Overview of head and neck cancer
  - Definition
    - Head and neck cancers comprise around 6% of all tumorsworldwide
  - Epidemiology
    - Incidence will continue to rise in line with the ageingpopulation
    - Mortality is high due to frequent late-stage diagnosis andlack of effective treatments
  - Treatment of head and neck cancer
- Unmet need in head and neck cancer
  - Summary of unmet needs
    - Currently available therapies induce modest response rates
    - High level of treatment-related morbidity and poor qualityof life
    - Early-stage diagnosis is limited, thereby compromisingsurvival
    - High economic burden
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Avastin (bevacizumab; Genentech/Roche/Chugai)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Tykerb (lapatinib; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Vectibix (panitumumab; Amgen)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Zalutumumab (HuMax-EGFR; Genmab/Medarex)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Alimta (pemetrexed; Eli Lilly)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Lipoplatin (liposomal cisplatin; Regulon)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Multikine (mixture of naturally occurring cytokines; CEL-SCI)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Proxinium (VB4-845; Viventia Biotech)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Advexin (contusugene; Introgen Therapeutics)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - INGN-241 (Introgen Therapeutics)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Superiority over current standard therapies is unlikely tobe shown by the current pipeline
CHAPTER 9 THYROID CANCER
- Overview of thyroid cancer
  - Definition
    - Thyroid cancer occurs more frequently in women and at ayounger age
  - Epidemiology
    - Incidence of thyroid cancer is rising due to increasinguse of ultrasound to detect small tumors
    - Thyroid cancer is one of the least deadly tumor types
  - Treatment of thyroid cancer
- Unmet need in thyroid cancer
  - Summary of unmet need
    - R&D interest is exceedingly low
    - Few alternative treatment options exist upon diseaserecurrence
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Zybrestat (combretastatin; OXiGENE)
    - Drug overview
    - Key historical events
    - Clinical development in thyroid cancer
    - Datamonitor comments
  - Axitinib (AG-13736; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in thyroid cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Axitinib and Zybrestat could form viable therapies wherefew alternative treatment options exist
APPENDIX A
- Bibliography
- List of tables
- List of figures
- List of abbreviations
- Methodology
  - Datamonitor forecast methodology
    - Epidemiology forecasts
    - Product forecasts
  - Datamonitor drug assessment summary
APPENDIX B
- About Datamonitor
  - About Datamonitor Healthcare
- Datamonitor Healthcare' s therapy area capabilities
  - About the Disease analysis team
  - Disclaimer
List of Tables
- Table 1: Late-phase cytotoxics pipeline for NSCLC, SCLC,mesothelioma, primary brain cancer, head and neck cancer, and thyroidcancer, 2008
- Table 2: Late-phase targeted therapies pipeline forNSCLC, SCLC, mesothelioma, primary brain cancer, head and neck cancer, andthyroid cancer, 2008
- Table 3: Late-phase immunotherapies pipeline for NSCLC,SCLC, mesothelioma, primary brain cancer, head and neck cancer, andthyroid cancer, 2008
- Table 4: Late-phase gene therapies pipeline for NSCLC,SCLC, mesothelioma, primary brain cancer, head and neck cancer, andthyroid cancer, 2008
- Table 5: Pipeline split by developmental phase andindication, 2008
- Table 6: Forecast incidence of NSCLC in the seven majorpharmaceutical markets, 2002-2017
- Table 7: Phase III NSCLC pipeline, 2008 (targetedtherapies)
- Table 8: Phase III NSCLC pipeline, 2008 (cytotoxic andimmunotherapies)
- Table 9: Phase II NSCLC pipeline, 2008 (targetedtherapies)
- Table 10: Phase II NSCLC pipeline, 2008 (cytotoxics)
- Table 11: Phase II NSCLC pipeline, 2008 (immunotherapiesand others)
- Table 12: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 1 of 4)
- Table 13: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 2 of 4)
- Table 14: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 3 of 4)
- Table 15: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 4 of 4)
- Table 16: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (cytotoxic therapies, 1 of2)
- Table 17: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (cytotoxic therapies, 2 of2)
- Table 18: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (immunotherapies)
- Table 19: Pipeline NSCLC product sales forecasts acrossthe seven major markets, 2008-2017 ($m)
- Table 20: Avastin: key historical facts
- Table 21: Taxotere: key historical facts
- Table 22: Erbitux: key historical events
- Table 23: Clinical development of Erbitux in NSCLC, 2008
- Table 24: Preliminary results of Erbitux withcarboplatin and a taxane in first-line NSCLC (BMS-099)
- Table 25: Nexavar: key historical events
- Table 26: Clinical development of Nexavar in NSCLC, 2008
- Table 27: Sutent: key historical events
- Table 28: Clinical development of Sutent in NSCLC, 2008
- Table 29: Tovok: key historical events
- Table 30: Clinical development of Tovok in NSCLC, 2008
- Table 31: Vargatef: key historical events
- Table 32: Zactima' s multiple anticancer targets
- Table 33: Zactima: key historical events
- Table 34: Clinical development of Zactima in NSCLC, 2008
- Table 35: Zolinza: key historical events
- Table 36: Clinical development of Zolinza in NSCLC, 2008
- Table 37: Aflibercept: key historical events
- Table 38: Clinical development of aflibercept in NSCLC,2008
- Table 39: ASA-404: key historical events
- Table 40: Clinical development of ASA-404 in NSCLC, 2008
- Table 41: CBT-1: key historical events
- Table 42: Clinical development of CBT-1 in NSCLC, 2008
- Table 43: CP-751871: key historical events
- Table 44: Clinical development of CP-751871 in NSCLC,2008
- Table 45: Motesanib: key historical events
- Table 46: Clinical development of motesanib in NSCLC,2008
- Table 47: Abraxane: key historical events
- Table 48: Clinical development of Abraxane in NSCLC,2008
- Table 49: Glutoxim: key historical events
- Table 50: Clinical development of Glutoxim in NSCLC,2008
- Table 51: Javlor: key historical events
- Table 52: Clinical development of Javlor in NSCLC, 2008
- Table 53: Lipoplatin: key historical events
- Table 54: Clinical development of Lipoplatin in NSCLC,2008
- Table 55: Taxoprexin: key historical events
- Table 56: Clinical development of Taxoprexin in NSCLC,2008
- Table 57: Opaxio: key historical events
- Table 58: Clinical development of Opaxio in NSCLC, 2008
- Table 59: STELLAR 2: Phase III results for Opaxio versusTaxotere in second-line NSCLC in patients with PS0-2
- Table 60: STELLAR 3: Phase III results for Opaxio pluscarboplatin in first-line NSCLC in patients with PS2
- Table 61: STELLAR 4: Phase III results for Opaxio versusGemzar or vinorelbine in first-line NSCLC in patients with PS2
- Table 62: Clinical development of Opaxio in women withadvanced NSCLC and normal estrogen levels: the PTG306 and PTG307 trials
- Table 63: Lucanix: key historical events
- Table 64: Clinical development of Lucanix in NSCLC, 2008
- Table 65: Stimuvax: key historical events
- Table 66: Clinical development of Stimuvax in NSCLC,2008
- Table 67: MAGE-A3 ASCI: key historical events
- Table 68: Clinical development of MAGE-A3 ASCI in NSCLC,2007
- Table 69: Classification of SCLC: the Veteran' sAdministration Lung Cancer Study Group (VALCSG) staging system
- Table 70: Datamonitor' s forecast incidence of SCLC inthe seven major pharmaceutical markets, 2002-2017
- Table 71: Phase III SCLC pipeline, 2008
- Table 72: Phase II SCLC pipeline, 2008 (targetedtherapies)
- Table 73: Phase II SCLC pipeline, 2008 (cytotoxics andimmunotherapies)
- Table 74: Forecasting assumptions for picoplatin in SCLCacross the seven major pharmaceutical markets, 2008
- Table 75: Picoplatin sales forecasts across the sevenmajor markets, 2008-2017 ($m)
- Table 76: Hycamtin: key historical facts
- Table 77: Picoplatin: key historical events
- Table 78: Clinical development of picoplatin in SCLC,2008
- Table 79: Epidemiologic features of malignantmesothelioma, 2005
- Table 80: Late-phase mesothelioma pipeline, 2008
- Table 81: Phase II mesothelioma pipeline, 2008
- Table 82: Forecasting assumptions for pipelinemesothelioma products across the seven major markets, 2008
- Table 83: Pipeline mesothelioma product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Table 84: Alimta: key facts
- Table 85: Onconase: key historical events
- Table 86: Zolinza: key historical events
- Table 87: Clinical development of Zolinza inmesothelioma, 2008
- Table 88: Estimated incidence of brain cancer in theseven major pharmaceutical markets, 2002-2017
- Table 89: Phase III brain cancer pipeline, 2008
- Table 90: Phase II brain cancer pipeline, 2008 (targetedtherapies)
- Table 91: Phase II brain cancer pipeline, 2008(cytotoxics)
- Table 92: Phase II brain cancer pipeline, 2008 (others)
- Table 93: Forecasting assumptions for pipeline braincancer products across the seven major markets, 2008
- Table 94: Pipeline brain cancer product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Table 95: Temodar: key facts
- Table 96: Theraloc: key historical events
- Table 97: Clinical development of Theraloc in braincancer, 2008
- Table 98: Cerepro: key historical events
- Table 99: Clinical development of Cerepro in braincancer, 2008
- Table 100: Risk factors for subtypes of head and neckcancer
- Table 101: Estimated incidence of head and neck cancerin the seven major pharmaceutical markets, 2002-2017
- Table 102: Phase III head and neck cancer pipeline, 2008
- Table 103: Phase II head and neck cancer pipeline, 2008(targeted therapies)
- Table 104: Phase II head and neck cancer pipeline, 2008(cytotoxics)
- Table 105: Phase II head and neck cancer pipeline, 2008(others)
- Table 106: Forecasting assumptions for pipeline head andneck cancer products across the seven major markets, 2008 (1 of 3)
- Table 107: Forecasting assumptions for pipeline head andneck cancer products across the seven major markets, 2008 (2 of 3)
- Table 108: Forecasting assumptions for pipeline head andneck cancer products across the seven major markets, 2008 (3 of 3)
- Table 109: Pipeline head and neck cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Table 110: Erbitux: key facts
- Table 111: Avastin: key historical events
- Table 112: Clinical development of Avastin in head andneck cancer, 2008
- Table 113: Tarceva: key historical events
- Table 114: Clinical development of Tarceva in head andneck cancer, 2008
- Table 115: Tykerb: key historical events
- Table 116: Clinical development of Tykerb in head andneck cancer, 2008
- Table 117: Vectibix: key historical events
- Table 118: Clinical development of Vectibix in head andneck cancer, 2008
- Table 119: Zalutumumab: key historical events
- Table 120: Clinical development of zalutumumab in headand neck cancer, 2008
- Table 121: Alimta: key historical events
- Table 122: Clinical development of Alimta in head andneck cancer, 2008
- Table 123: Lipoplatin: key historical events
- Table 124: Clinical development of Lipoplatin in headand neck cancer, 2008
- Table 125: Multikine: key historical events
- Table 126: Clinical development of Multikine in head andneck cancer, 2008
- Table 127: Proxinium: key historical events
- Table 128: Clinical development of Proxinium in head andneck cancer, 2008
- Table 129: Advexin: key historical events
- Table 130: Clinical development for Advexin in head andneck cancer, 2008
- Table 131: INGN-241: key historical events
- Table 132: Estimated incidence of thyroid cancer in theseven major pharmaceutical markets, 2002-2017
- Table 133: Five-year survival rates by stage of thyroidcancer
- Table 134: Phase III thyroid cancer pipeline, 2008
- Table 135: Phase II thyroid cancer pipeline, 2008
- Table 136: Forecasting assumptions for pipeline thyroidcancer products across the seven major markets, 2008
- Table 137: Pipeline thyroid cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Table 138: Doxil: key facts
- Table 139: Zybrestat: key historical events
- Table 140: Clinical development of Zybrestat in thyroidcancer, 2008
- Table 141: Axitinib: key historical events
- Table 142: Phase II development of axitinib in thyroidcancer, 2007
- Table 143: List of abbreviations
- Table 144: Datamonitor drug assessment parameters
List of Figures
- Figure 1: Forecast incidence and mortality from NSCLC in2008 and 2017 across the seven major markets
- Figure 2: The role of surgery, chemotherapy andradiotherapy in the management of NSCLC
- Figure 3: Summary of unmet needs in the NSCLC market
- Figure 4: Datamonitor drug assessment summary for themolecular targeted therapies in late-phase development for NSCLC, 2008
- Figure 5: Datamonitor drug assessment summary for thecytotoxic therapies in late-phase development for NSCLC, 2008
- Figure 6: Datamonitor drug assessment summary for theimmunotherapies in late-phase development for NSCLC, 2008
- Figure 7: Pipeline NSCLC targeted therapies salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 8: Pipeline NSCLC cytotoxic therapies salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 9: Pipeline NSCLC immunotherapies sales forecastsacross the seven major markets, 2008-2017 ($m)
- Figure 10: Phase III FLEX trial results
- Figure 11: Phase II results for first-line Erbitux withchemoradiotherapy in locally advanced NSCLC
- Figure 12: Phase II results for Nexavar monotherapy insecond- or third-line NSCLC
- Figure 13: Phase II results of third-line Nexavarmonotherapy: randomized discontinuation design
- Figure 14: Phase II results for Sutent monotherapy insecond- or third-line NSCLC
- Figure 15: Phase I results for Tovok in patients withadvanced solid malignancies
- Figure 16: Phase II results for Vargatef monotherapy insecond- or third-line NSCLC
- Figure 17: Phase II results for Zactima with carboplatinand paclitaxel in first-line NSCLC
- Figure 18: Phase II results for Zactima with Taxotere insecond-line NSCLC
- Figure 19: Phase II results for Zactima versus Iressa inadvanced NSCLC
- Figure 20: Phase III studies of Zactima in NSCLC
- Figure 21: Phase II results for Zolinza monotherapy insecond-line NSCLC
- Figure 22: Interim Phase II results for afliberceptmonotherapy in third-line NSCLC
- Figure 23: Phase II results for ASA-404 withchemotherapy in first-line NSCLC
- Figure 24: Phase Ib/II results for ASA-404 withchemotherapy in first-line NSCLC
- Figure 25: Interim Phase II results for CP-751871 withchemotherapy in first-line NSCLC
- Figure 26: Phase Ib results for motesanib withcarboplatin and paclitaxel or Vectibix in first- or second-line NSCLC
- Figure 27: Interim Phase II results for Abraxane withcarboplatin and Avastin in first-line NSCLC
- Figure 28: Phase II results for Abraxane monotherapy infirst-line NSCLC
- Figure 29: Phase I/II results for Glutoxim withchemotherapy in first-line NSCLC
- Figure 30: Phase III results for Javlor versus Taxoterein second-line NSCLC
- Figure 31: Interim Phase III results for Lipoplatin withGemzar in first-line NSCLC
- Figure 32: Interim Phase III results for Lipoplatin withpaclitaxel in first-line NSCLC
- Figure 33: Phase II results for Taxoprexin monotherapyin first-line NSCLC
- Figure 34: Phase II results for Lucanix in advancedNSCLC
- Figure 35: Phase IIb results for Stimuvax maintenancetherapy in advanced NSCLC
- Figure 36: Phase II results for MAGE-A3 ASCI as adjuvanttherapy in completely resected Stage IB/II NSCLC
- Figure 37: Forecast incidence and mortality from NSCLCin 2008 and 2017 across the seven major markets
- Figure 38: Overview of SCLC treatment
- Figure 39: Summary of unmet needs in the SCLC market
- Figure 40: Datamonitor drug assessment summary forpicoplatin in SCLC, 2008
- Figure 41: Picoplatin sales forecasts across the sevenmajor markets, 2008-2017 ($m)
- Figure 42: Phase II results for picoplatin insecond-line SCLC
- Figure 43: Five-year survival rates for mesothelioma inthe US, 1975-1998
- Figure 44: Summary of unmet needs in the mesotheliomamarket
- Figure 45: Datamonitor drug assessment summary for thepipeline mesothelioma products, 2008
- Figure 46: Pipeline mesothelioma product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Figure 47: Phase III results for first- or second-linedoxorubicin with or without Onconase in mesothelioma patients
- Figure 48: Phase I results for second-line Zolinza inmesothelioma patients
- Figure 49: Incidence and mortality from brain cancer in2008 and 2017 across the seven major markets
- Figure 50: Summary of unmet needs in the primary braincancer market
- Figure 51: Datamonitor drug assessment summary for thepipeline brain cancer products, 2008
- Figure 52: Pipeline brain cancer product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Figure 53: Phase II results for Theraloc in relapsed orrefractory pediatric high-grade gliomas
- Figure 54: Phase II trial investigating Cerepro inprimary and recurrent glioma patients
- Figure 55: Incidence and mortality from head and neckcancer in 2008 and 2017 across the seven major markets
- Figure 56: Summary of unmet needs in the head and neckcancer market
- Figure 57: Datamonitor drug assessment summary for thepipeline head and neck cancer products, 2008
- Figure 58: Pipeline head and neck cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 59: Phase II results for first-line Alimta andAvastin in advanced head and neck cancer
- Figure 60: Phase II study investigating Avastin withconcurrent radiotherapy and Taxotere in head and neck cancer
- Figure 61: Interim Phase II results for first-lineTarceva, Taxotere and cisplatin in metastatic or recurrent head and neckcancer
- Figure 62: Phase II results for first-line Tarceva,cisplatin and radiotherapy for locally advanced head and neck cancer
- Figure 63: Phase II results for third-line Tykerb inrecurrent or metastatic head and neck cancer
- Figure 64: Preliminary Phase I results for first-lineVectibix and chemoradiotherapy in Stage III/IV head and neck cancer
- Figure 65: Phase I/II trial results for second-linezalutumumab in patients with recurrent squamous cell head and neck cancer
- Figure 66: Phase II results for first-line Alimta andAvastin in advanced head and neck cancer
- Figure 67: Phase II results for first-line Alimta inadvanced head and neck cancer
- Figure 68: Phase II trial and follow-up results forneoadjuvant Multikine in head and neck cancer
- Figure 69: Interim Phase III results for second-lineProxinium in advanced head and neck cancer
- Figure 70: Phase I dose-escalation trial for Proxiniumin advanced head and neck cancer
- Figure 71: Preliminary results from the Phase III T301study comparing second-line Advexin with methotrexate in recurrent headand neck cancer
- Figure 72: Incidence and mortality from thyroid cancerin 2008 and 2017 across the seven major markets
- Figure 73: Summary of unmet needs in the thyroid cancermarket
- Figure 74: Datamonitor drug assessment summary for thepipeline thyroid cancer products, 2008
- Figure 75: Pipeline thyroid cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 76: Phase II results for first-line Zybrestat inadvanced anaplastic thyroid cancer patients
- Figure 77: Phase II results for axitinib in thyroidcancer patients refractory or unsuitable for radioiodine therapy
- Figure 78: Datamonitor drug assessment summary ofpipeline molecular targeted therapies in development for hematologicalmalignancies, 2007

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

癌症概要：肺癌・腦瘤・頭頸部癌・甲狀腺癌

Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid